Design, Synthesis and Biological Evaluation of a Series of 5- and 7-hydroxycoumarin Derivatives as 5-HT_{1A} Serotonin Receptor Antagonists

Kinga Ostrowska^{1,*}, Anna Leśniak², Zuzanna Czarnocka¹, Jagoda Chmiel¹, Magdalena Bujalska-Zadrożny² and Bartosz Trzaskowski³

- ¹ Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Str., 02 097 Warsaw, Poland, kostrowska@wum.edu.pl, zuzanna.czarnocka@gmail.com, jagodachmiel178096@gmail.com
- ² Department of Pharmacodynamics, Faculty of Pharmacy, Centre for Preclinical Research and Technology, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland, anna.lesniak@wum.edu.pl, magdalena.bujalska@wum.edu.pl
- ³ Centre of New Technologies, University of Warsaw, 2C Banacha Str., 02-097 Warszawa, b.trzaskowski@cent.uw.edu.pl
- * Correspondence: kostrowska@wum.edu.pl ; Tel.: +48-22-572-0669



1a-1j



3a-3j







Figure 1S. Atom Numbering of compounds 1a-1j, 2a-2j, 3a-3j, 4a-4j, 5a-5j, 6a-6j.

¹H NMR and ¹³C NMR Spectra









1a







Ac



Ac





Ad



1e



1e









/







Λī



/











2e









X







2d



2d



2e


,





C





2.



2h



KO-335-1H-cdcl3 6.05 14 12 95 95 95 6.76 181 4.22 4.20 4.18 2.295 2.995 2.995 2.993 2.93 2.93 2.55 2.54 2.55 2.54 2.55 2.54 2.55 2.54 2.55 2.54 2.55 2.54 2.55 -0.00 - 1.25 KO 335 1H w CDCl3 2i CI ĊI 0 0 0.19 0.14 1.00 0.92 0.92 0.92 0.94-1.91-3.92[/] 1.97⁻ 3.43⁻ 2.93⁻ 2.73-1 0.14-1 0.19 1.62-8.0 7.0 7.5 6.5 6.0 4.5 4.0 f1 (ppm) 5.5 5.0 3.0 3.5 2.5 2.0 1.5 0.5 1.0 0.0

T 8.5



2,



2)



2)







Sa



3ã



- 22













Be

















(/



Bi



SA



3j







Ya


((













Yd



















6.1

×.













 $\delta_{i} = \delta_{i}$

5a



5a





5.6







5d



5-d



Se



5e














Sh



5.0



5ĩ



5%









6a



6a



6b







6 C





6d



6e



6e













6h



6.









Figure S2. Ligand interaction diagram for compound **1a** docked to $5HT_{1A}$ receptor.



Figure S3. Ligand interaction diagram for compound **1b** docked to $5HT_{1A}$ receptor.



Figure S4. Ligand interaction diagram for compound **2a** docked to 5HT_{1A} receptor.



Figure S5. Ligand interaction diagram for compound **2b** docked to 5HT_{1A} receptor.



Figure S6. Ligand interaction diagram for compound **3a** docked to 5HT_{1A} receptor.



Figure S7. Ligand interaction diagram for compound **3b** docked to $5HT_{1A}$ receptor.



Figure S8. Ligand interaction diagram for compound **4a** docked to $5HT_{1A}$ receptor.



Figure S9. Ligand interaction diagram for compound **4b** docked to $5HT_{1A}$ receptor.



Figure S10. Ligand interaction diagram for compound **5a** docked to 5HT_{1A} receptor.


Figure S11. Ligand interaction diagram for compound **5b** docked to $5HT_{1A}$ receptor.



Figure S12. Ligand interaction diagram for compound **6a** docked to $5HT_{1A}$ receptor.



Figure S13. Ligand interaction diagram for compound **6b** docked to 5HT_{1A} receptor.



Figure S14. Ligand interaction diagram for compound 1j docked to $5HT_{1A}$ receptor.



Figure S15. Ligand interaction diagram for compound **5f** docked to $5HT_{1A}$ receptor.



Figure S16. Ligand interaction diagram for compound 5g docked to $5HT_{1A}$ receptor.



Figure S17. Ligand interaction diagram for compound **5h** docked to $5HT_{1A}$ receptor.



Figure S18. Ligand interaction diagram for compound **1***j* docked to 5HT_{2A} receptor.



Figure S19. Ligand interaction diagram for compound **5f** docked to $5HT_{2A}$ receptor.



Figure S20. Ligand interaction diagram for compound **5g** docked to $5HT_{2A}$ receptor.



Figure S21. Ligand interaction diagram for compound **5h** docked to 5HT_{2A} receptor.